Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microglandular adenosis, triple negative breast carcinoma and DNA repair defects.

Journal of clinical pathology·2026
Same author

Epidemiological study of overall survivability of individuals diagnosed with lung and bronchus cancer in Michigan between the years 1996 and 2017.

Thoracic cancer·2024
Same author

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

Patient, family caregiver, and economic outcomes of an integrated screening and novel stepped collaborative care intervention in the oncology setting in the USA (CARES): a randomised, parallel, phase 3 trial.

Lancet (London, England)·2024
Same author

Venous Thromboembolism Risk Assessment in Hospitalized Cancer Patients: A Single Center Study.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2023
Same author

Maintenence rituximab following induction in autoimmune cytopenias.

British journal of haematology·2023
Same journal

Post-extubation pneumothorax following bougie-assisted endotracheal tube exchange.

BMJ case reports·2026
Same journal

Cardiac tamponade secondary to hypothyroidism.

BMJ case reports·2026
Same journal

Unmasking a rare contrast reaction: acute non-cardiogenic pulmonary oedema after iohexol injection.

BMJ case reports·2026
Same journal

Water gonioscopy-assisted transluminaltrabeculotomy.

BMJ case reports·2026
Same journal

<i>Clostridioides difficile</i> osteomyelitis presenting as a Brodie's abscess of the tibia.

BMJ case reports·2026
Same journal

Steroid refractory rapidly progressing organising pneumonia.

BMJ case reports·2026
See all related articles

Related Experiment Video

Updated: Feb 14, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

538

Hepatotoxicity Associated With Vismodegib.

Prabhjot S Bedi1, Manoj P Rai2, Nishant Tageja3

  • 1Department of Internal Medicine, UPMC East, Monroeville, Pennsylvania, USA.

BMJ Case Reports
|February 14, 2018
PubMed
Summary
This summary is machine-generated.

Vismodegib, a cancer drug, can cause liver damage (hepatotoxicity) in patients. This case highlights the importance of considering drug-induced liver injury in patients presenting with elevated liver enzymes.

Keywords:
liver diseaseoncologyunwanted effects / adverse reactions

More Related Videos

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

11.1K
Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier
09:00

Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier

Published on: April 5, 2017

20.9K

Related Experiment Videos

Last Updated: Feb 14, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

538
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

11.1K
Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier
09:00

Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier

Published on: April 5, 2017

20.9K

Area of Science:

  • Hepatology
  • Oncology
  • Pharmacology

Background:

  • Basal cell carcinoma (BCC) is a common skin cancer.
  • Vismodegib is a targeted therapy used for advanced BCC.
  • Drug-induced liver injury (DILI) is a significant concern in pharmacotherapy.

Observation:

  • An 82-year-old female patient on vismodegib developed nausea, vomiting, and abdominal pain.
  • Elevated liver enzymes were noted in laboratory results.
  • Biliary obstruction was ruled out via imaging studies (ERCP and PTC).

Findings:

  • Despite biliary drainage, bilirubin levels continued to rise.
  • Infections, autoimmune hepatitis, and other hepatotoxic drugs were excluded.
  • Vismodegib was identified as the most probable cause of the patient's hepatotoxicity.

Implications:

  • This case underscores the potential hepatotoxicity of vismodegib.
  • Clinicians should monitor liver function in patients receiving vismodegib.
  • Early recognition and management of DILI are crucial for patient outcomes.